Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Core Insights - Vertex Pharmaceuticals announced positive data from a Phase 4 study of JOURNAVX® (suzetrigine), a non-opioid pain signal inhibitor for treating moderate-to-severe acute pain in adults [1] - The study demonstrated effective pain management and facilitated opioid-free recovery following various plastic surgical procedures [1] - A significant finding was that 90.9% of patients in the study remained opioid-free by the end of treatment [1]